<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Vitamin D &#8211; mikrobik.net</title>
	<atom:link href="https://wp.mikrobik.net/tag/vitamin-d/feed/" rel="self" type="application/rss+xml" />
	<link>https://wp.mikrobik.net</link>
	<description></description>
	<lastBuildDate>Wed, 02 Jul 2025 18:33:14 +0000</lastBuildDate>
	<language>tr</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.1</generator>
	<item>
		<title>Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline</title>
		<link>https://wp.mikrobik.net/vitamin-d-for-the-prevention-of-disease-an-endocrine-society-clinical-practice-guideline/</link>
		
		<dc:creator><![CDATA[mikrobik]]></dc:creator>
		<pubDate>Thu, 24 Apr 2025 12:57:00 +0000</pubDate>
				<category><![CDATA[Biyokimya Rehberleri]]></category>
		<category><![CDATA[Vitamin D]]></category>
		<guid isPermaLink="false"></guid>

					<description><![CDATA[Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline Marie B Demay , Anastassios G Pittas , Daniel D Bikle , Dima L Diab , Mairead E Kiely ,...]]></description>
										<content:encoded><![CDATA[<p><strong>V<span style="color:#5C3566;">itamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline </span></strong><br />
Marie B Demay , Anastassios G Pittas , Daniel D Bikle , Dima L Diab , Mairead E Kiely , Marise Lazaretti-Castro , Paul Lips , Deborah M Mitchell , M Hassan Murad , Shelley Powers , Sudhaker D Rao , Robert Scragg , John A Tayek , Amy M Valent , Judith M E Walsh , Christopher R McCartney<br />
Author Notes<br />
The Journal of Clinical Endocrinology &#038; Metabolism, Volume 109, Issue 8, August 2024, Pages 1907–1947, https://<a href="https://academic.oup.com/jcem/article/109/8/1907/7685305" target="_blank" rel="noopener">doi.org/10.1210/clinem/dgae290</a></p>
<p><strong>Background</strong><br />
Numerous studies demonstrate associations between serum concentrations of 25-hydroxyvitamin D (25[OH]D) and a variety of common disorders, including musculoskeletal, metabolic, cardiovascular, malignant, autoimmune, and infectious diseases. Although a causal link between serum 25(OH)D concentrations and many disorders has not been clearly established, these associations have led to widespread supplementation with vitamin D and increased laboratory testing for 25(OH)D in the general population. The benefit-risk ratio of this increase in vitamin D use is not clear, and the optimal vitamin D intake and the role of testing for 25(OH)D for disease prevention remain uncertain.</p>
<p><strong>Objective</strong><br />
To develop clinical guidelines for the use of vitamin D (cholecalciferol [vitamin D3] or ergocalciferol [vitamin D2]) to lower the risk of disease in individuals without established indications for vitamin D treatment or 25(OH)D testing.</p>
<p><strong>Methods</strong><br />
A multidisciplinary panel of clinical experts, along with experts in guideline methodology and systematic literature review, identified and prioritized 14 clinically relevant questions related to the use of vitamin D and 25(OH)D testing to lower the risk of disease. The panel prioritized randomized placebo-controlled trials in general populations (without an established indication for vitamin D treatment or 25[OH]D testing), evaluating the effects of empiric vitamin D administration throughout the lifespan, as well as in select conditions (pregnancy and prediabetes). The panel defined “empiric supplementation” as vitamin D intake that (a) exceeds the Dietary Reference Intakes (DRI) and (b) is implemented without testing for 25(OH)D. Systematic reviews queried electronic databases for publications related to these 14 clinical questions. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology was used to assess the certainty of evidence and guide recommendations. The approach incorporated perspectives from a patient representative and considered patient values, costs and resources required, acceptability and feasibility, and impact on health equity of the proposed recommendations. The process to develop this clinical guideline did not use a risk assessment framework and was not designed to replace current DRI for vitamin D.</p>
<p><strong>Results</strong><br />
The panel suggests empiric vitamin D supplementation for children and adolescents aged 1 to 18 years to prevent nutritional rickets and because of its potential to lower the risk of respiratory tract infections; for those aged 75 years and older because of its potential to lower the risk of mortality; for those who are pregnant because of its potential to lower the risk of preeclampsia, intra-uterine mortality, preterm birth, small-for-gestational-age birth, and neonatal mortality; and for those with high-risk prediabetes because of its potential to reduce progression to diabetes. Because the vitamin D doses in the included clinical trials varied considerably and many trial participants were allowed to continue their own vitamin D–containing supplements, the optimal doses for empiric vitamin D supplementation remain unclear for the populations considered. For nonpregnant people older than 50 years for whom vitamin D is indicated, the panel suggests supplementation via daily administration of vitamin D, rather than intermittent use of high doses. The panel suggests against empiric vitamin D supplementation above the current DRI to lower the risk of disease in healthy adults younger than 75 years. No clinical trial evidence was found to support routine screening for 25(OH)D in the general population, nor in those with obesity or dark complexion, and there was no clear evidence defining the optimal target level of 25(OH)D required for disease prevention in the populations considered; thus, the panel suggests against routine 25(OH)D testing in all populations considered. The panel judged that, in most situations, empiric vitamin D supplementation is inexpensive, feasible, acceptable to both healthy individuals and health care professionals, and has no negative effect on health equity.</p>
<p><strong>Conclusion</strong><br />
The panel suggests empiric vitamin D for those aged 1 to 18 years and adults over 75 years of age, those who are pregnant, and those with high-risk prediabetes. Due to the scarcity of natural food sources rich in vitamin D, empiric supplementation can be achieved through a combination of fortified foods and supplements that contain vitamin D. Based on the absence of supportive clinical trial evidence, the panel suggests against routine 25(OH)D testing in the absence of established indications. These recommendations are not meant to replace the current DRIs for vitamin D, nor do they apply to people with established indications for vitamin D treatment or 25(OH)D testing. Further research is needed to determine optimal 25(OH)D levels for specific health benefits.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Vitamin D Assays: Past and Present Debates, Difficulties and Developments</title>
		<link>https://wp.mikrobik.net/vitamin-d-assays-past-and-present-debates-difficulties-and-developments/</link>
		
		<dc:creator><![CDATA[mikrobik]]></dc:creator>
		<pubDate>Wed, 05 Sep 2018 12:53:00 +0000</pubDate>
				<category><![CDATA[Biyokimya Derlemeleri]]></category>
		<category><![CDATA[Vitamin D]]></category>
		<guid isPermaLink="false"></guid>

					<description><![CDATA[Vitamin D Assays: Past and Present Debates, Difficulties and Developments William D. Fraser • Anna M. Milan Calcif Tissue Int (2013) 92:118–127 Abstract Clinical interest in Vitamin D and its purported roles not...]]></description>
										<content:encoded><![CDATA[<p><strong>Vitamin D Assays: Past and Present Debates, Difficulties and Developments</strong><br />
William D. Fraser • Anna M. Milan</p>
<p><a href="https://link.springer.com/content/pdf/10.1007%2Fs00223-012-9693-3.pdf" target="_blank" rel="noopener">Calcif Tissue Int (2013) 92:118–127</a></p>
<p>Abstract Clinical interest in Vitamin D and its purported roles not only in calcium and bone metabolism but in several other medical conditions (diabetes, cardiovascular disease, multiple sclerosis, cancer, psychiatric disorders, neuro-muscular disease) has led to a surge in laboratory requests for 25 hydroxy vitamin D and 1,25 dihydroxy vitamin D measurement. Circulating 25 hydroxy vitamin D concentration is routinely used as the best indicator of vitamin D status, but measurement of other metabolites, especially the physiologically active 1,25 dihyroxy vitamin D, are of clinical value. Over the last 40 years the development of assays for vitamin D and its metabolites from early competitive binding assays through to immunoassay and liquid chromatography aligned to mass spectrometry have demonstrated various analytical challenges, the advantages and disadvantages of each method are constantly changing with new technological developments.<br />
Immunoassay remains the predominant mode of measurement for 25-hydroxy vitamin D although problems with equimolar recovery of the D2 and D3 metabolites remain an issue. Standardisation of all assays has been improved but not resolved with the currently available reference materials as evidenced by the international vitamin D external quality assurance scheme, DEQAS. The choice of method for each laboratory remains a balance mainly between turn around time, convenience, cost and the specificity and accuracy of the information obtained. With increasing discussion and clinical interest surrounding other vitamin D metabolites the vitamin D assay debate is set to continue.<br />
Keywords Steroid hormones, vitamin D  Assay</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>D Vitamini, Kalsiyum &#038; Mineral Metabolizması,</title>
		<link>https://wp.mikrobik.net/d-vitamini-kalsiyum-mineral-metabolizmasi/</link>
		
		<dc:creator><![CDATA[mikrobik]]></dc:creator>
		<pubDate>Thu, 28 May 2015 11:29:00 +0000</pubDate>
				<category><![CDATA[Biyokimya Derlemeleri]]></category>
		<category><![CDATA[Vitamin D]]></category>
		<guid isPermaLink="false"></guid>

					<description><![CDATA[D Vitamini, Kalsiyum &#038; Mineral Metabolizması, D Vitaminin İskelet Dışı Etkileri ve Kronik Böbrek Yetmezliğinde Nutrisyonel D Vitamini Kullanımı Ankara Med J, 2014, 14(4): 162-171 Vitamin D, güneş ışığı ile temas sonucu deride...]]></description>
										<content:encoded><![CDATA[<p><strong><span style="color:#5C3566;">D Vitamini, Kalsiyum &#038; Mineral Metabolizması, D Vitaminin İskelet Dışı Etkileri ve Kronik Böbrek Yetmezliğinde Nutrisyonel D Vitamini Kullanımı</span></strong></p>
<p><a href="http://www.ankaramedicaljournal.com/article/viewFile/1047000154/pdf_5" target="_blank" rel="noopener">Ankara Med J, 2014, 14(4): 162-171</a></p>
<p>Vitamin D, güneş ışığı ile temas sonucu deride üretilen, yağda çözünen, secosteroid yapıda bir prohormondur. Vücutta çeşitli metabolik değişikliklerle kalsitriol olarak bilinen, kalsiyum ve fosfor metabolizmasında önemli rol oynayan bir hormona dönüşür. Böbrek dokusu haricinde D vitaminine ait reseptörler; T lenfositler, beyin, prostat, pankreas, gonadlar, meme dokusu, kas ve kolon gibi birçok organ ve dokuda bulunmaktadır. D vitamininin etkinliği sadece kalsiyum homeostazisini düzenleyerek kemik sağlığını idame ettirmekle sınırlı olmayıp, aynı zamanda pro-apopitotik, antienflamatuar ve immün-modülatuar özelliklere sahip olduğu bildirilmektedir. Son yıllarda yapılan epidemiyolojik çalışmalarda, düşük D vitamini düzeyinin kanser insidansını ve kardiyovasiküler mortaliteyi arttırdığı, diyabet ve multipl skleroz gibi otoimmün hastalıklar ile birlikte olduğu bildirilmiştir.<br />
Kronik böbrek yetmezliğinin (KBY) gelişmesi, 1,25 dihidroksi D vitamini üretiminde progresif azalma ile ilişkilidir. Düşük 25-hidroksi vitamin D seviyeleri kronik böbrek yetmezliğinin tüm evrelerinde gözlenmekte ve sekonder hiperparatiroidizme neden olmaktadır. KBY hastalarında bilinen D vitamini önemli biyolojik etkileri, 25 hidroksi vitamin D’nin 1-25 dihidroksi D vitaminine extrarenal dönüşümü sayesinde gerçekleşmektedir. Bu derleme D vitamini, kalsiyum-mineral metabolizması, D vitaminin iskelet dışı etkileri ve kronik böbrek yetmezliğinde nutrisyonel D vitamini kullanımı gözden geçirilmiştir.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>25-OH-Vitamin D Hormon için Tandem Kütle Spektrometrede Yöntem Geçerli Kılma Çalışması ve Bu Yöntemin Farklı Yöntemlerle Karşılaştırılması</title>
		<link>https://wp.mikrobik.net/25-oh-vitamin-d-hormon-icin-tandem-kutle-spektrometrede-yontem-gecerli-kilma-calismasi-ve-bu-yontemin-farkli-yontemlerle-karsilastirilmasi/</link>
		
		<dc:creator><![CDATA[mikrobik]]></dc:creator>
		<pubDate>Fri, 06 Dec 2013 15:23:00 +0000</pubDate>
				<category><![CDATA[Biyokimya Derlemeleri]]></category>
		<category><![CDATA[Vitamin D]]></category>
		<guid isPermaLink="false"></guid>

					<description><![CDATA[25-OH-Vitamin D Hormon için Tandem Kütle Spektrometrede Yöntem Geçerli Kılma Çalışması ve Bu Yöntemin Farklı Yöntemlerle Karşılaştırılması Birsen Sahillioğlu, Muhittin A. Serdar, Neslihan Erkal, Gönül Erden, Fatih Bakır, Mustafa Metin Yıldırımkaya, Serhat Işık,...]]></description>
										<content:encoded><![CDATA[<p><strong><span style="color:#5C3566;">25-OH-Vitamin D Hormon için Tandem Kütle Spektrometrede Yöntem Geçerli Kılma Çalışması ve Bu Yöntemin Farklı Yöntemlerle Karşılaştırılması</span></strong><br />
Birsen Sahillioğlu, Muhittin A. Serdar, Neslihan Erkal, Gönül Erden, Fatih Bakır, Mustafa Metin Yıldırımkaya, Serhat Işık, Ufuk Özuğuz</p>
<p><a href="http://www.turkjbiochem.com/2011/073-079.pdf" target="_blank" rel="noopener">Türk Biyokimya Dergisi [Turkish Journal of Biochemistry–Turk J Biochem] 2011; 36 (1) ; 73–79</a></p>
<p>Amaç:<br />
25-hidroksivitamin D3’ün ölçülmesi vitamin D durumunun belirlenmesinde klinik bir belirleyici olarak kabul edilmiştir. 25-OH-vitamin D’nin klinik olarak doğru ölçülmesi çok büyük önem arz etmektedir. Bunun için bir standardizasyon gerekmektedir ve tandem kütle spektrometre (LC-MS/MS) yöntemi haricindeki yöntemler sadece toplam D vitamini miktarını verirler ve daha az hassastırlar. LC-MS/MS vitamin D değerlerini ölçmek için altın standart bir yöntemdir. Bu çalışmada buradan yola çıkılarak LC-MS/MS cihazında yeni bir yöntem geliştirilmiş, geçerli kılınmış ve bu yöntem HPLC, RIA, Kemiluminesans yöntemleriyle karşılaştırılmıştır.<br />
Gereç ve yöntemler:<br />
D3’ün rutin tesbitinde kararlı-izotop-işaretli internal standard (IS) ile beraber isotope-dilution liquid chromatography-tandem mass spektrometre (ID-LC-MS/MS) kullanılmıştır. Buradan elde edilen değerler HPLC , RIA ve kemiluminesans yöntemleriyle karşılaştırılmıştır.<br />
Bulgular:<br />
25-hidroksivitamin D3 için 6.5, 24 ve 43 ng/mL derişimlerinde gün içi CV (Belirsizlik katsayısı) sırasıyla 5.3%, 5.5% ve 5.6% olarak bulunmuştur. 25-hidroksivitamin D3 için mevcut yöntemin deteksiyon limiti <3,75 ng/mL olarak tesbit edildi. Yöntemin total çalışma zamanı 4 dakikadır. Yöntem karşılaştırması çalışmasında LC-MS/MS ile en iyi uyumu HPLC yöntemi gösterdi ve denklemi y = 4.3822 + 1.0124 x (R2= 0.96) olarak hesaplandı.
Sonuçlar:
LC-MS/MS yöntemine dayalı olarak RIA ve kemiluminesans yöntemlerinin rutin klinik çalışmalarda doğruluğunun yeterli olmadığı tesbit edildi. Altın standart yöntem olan LC-MS/MS ile en iyi uyumu HPLC yönteminin gösterdiği saptandı.
</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Vitamin D Deficiency in Adults: When to Test and How to Treat</title>
		<link>https://wp.mikrobik.net/vitamin-d-deficiency-in-adults-when-to-test-and-how-to-treat/</link>
		
		<dc:creator><![CDATA[mikrobik]]></dc:creator>
		<pubDate>Fri, 06 Dec 2013 15:00:00 +0000</pubDate>
				<category><![CDATA[Biyokimya Derlemeleri]]></category>
		<category><![CDATA[Vitamin D]]></category>
		<guid isPermaLink="false"></guid>

					<description><![CDATA[Vitamin D Deficiency in Adults: When to Test and How to Treat Kurt A. Kennel, Matthew T. Drake, and Daniel L. Hurley Mayo Clin Proc. 2010 August; 85(8): 752–758. Recent evidence for the...]]></description>
										<content:encoded><![CDATA[<p><strong><span style="color:#5C3566;">Vitamin D Deficiency in Adults: When to Test and How to Treat</span></strong><br />
Kurt A. Kennel, Matthew T. Drake, and Daniel L. Hurley</p>
<p><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2912737/pdf/mayoclinproc_85_8_009.pdf" target="_blank" rel="noopener">Mayo Clin Proc. 2010 August; 85(8): 752–758.</a> </p>
<p>Recent evidence for the nonskeletal effects of vitamin D, coupled with recognition that vitamin D deficiency is common, has revived interest in this hormone. Vitamin D is produced by skin exposed to ultraviolet B radiation or obtained from dietary sources, including supplements. Persons commonly at risk for vitamin D deficiency include those with inadequate sun exposure, limited oral intake, or impaired intestinal absorption. Vitamin D adequacy is best determined by measurement of the 25-hydroxyvitamin D concentration in the blood. Average daily vitamin D intake in the population at large and current dietary reference intake values are often inadequate to maintain optimal vitamin D levels. Clinicians may recommend supplementation but be unsure how to choose the optimal dose and type of vitamin D and how to use testing to monitor therapy. This review outlines strategies to prevent, diagnose, and treat vitamin D deficiency in adults.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Güncel Bilgiler Işığında Vitamin D</title>
		<link>https://wp.mikrobik.net/guncel-bilgiler-isiginda-vitamin-d/</link>
		
		<dc:creator><![CDATA[mikrobik]]></dc:creator>
		<pubDate>Mon, 28 Jan 2013 10:53:00 +0000</pubDate>
				<category><![CDATA[Biyokimya Derlemeleri]]></category>
		<category><![CDATA[Vitamin D]]></category>
		<guid isPermaLink="false"></guid>

					<description><![CDATA[Güncel Bilgiler Işığında Vitamin D Ayşe Tellioğlu, Sibel Başaran Archives Medical Review Journal. 2013; 22(2): 259-271 Vitamin D, kalsiyum ve fosfor hemostazının yanı sıra, aktif formu olan 1,25-dihidroksivitamin D3’ün nükleer vitamin D reseptörü...]]></description>
										<content:encoded><![CDATA[<p><strong><span style="color:#5C3566;">Güncel Bilgiler Işığında Vitamin D </span></strong><br />
Ayşe Tellioğlu, Sibel Başaran</p>
<p><a href="http://www.scopemed.org/fulltextpdf.php?mno=26967" target="_blank" rel="noopener">Archives Medical Review Journal. 2013; 22(2): 259-271</a></p>
<p>Vitamin D, kalsiyum ve fosfor hemostazının yanı sıra, aktif formu olan 1,25-dihidroksivitamin D3’ün nükleer vitamin D reseptörü aracılığı ile hücre diferansiyasyonu ve proliferasyonu ile ilgili birçok geni regüle etmektedir. Vitamin D’nin sağlıklı kemik gelişimi yanı sıra, antiinflamatuar, immünmodülatör özellikleri ve sitokin seviyeleri üzerine olası etkileri nedeniyle birçok kanser tipinin, otoimmun ve allerjik, kardiyovasküler ve enfeksiyon hastalıkların önlenmesinde rolü vardır. Düşük vitamin D seviyeleri kanserler, otoimmün hastalıklar, diyabet, hipertansiyon ve enfeksiyöz hastalıklar gibi birçok hastalığın artmış riskiyle ilişkilendirmektedir. Bu derlemede vitamin D ile ilgili güncel bilgiler, vitamin D’nin kas-iskelet sistemi ve diğer sistemler üzerine etkileri tartışılmıştır.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Perinatal D vitamini yetersizliği</title>
		<link>https://wp.mikrobik.net/perinatal-d-vitamini-yetersizligi/</link>
		
		<dc:creator><![CDATA[mikrobik]]></dc:creator>
		<pubDate>Mon, 16 Jul 2012 12:27:24 +0000</pubDate>
				<category><![CDATA[Biyokimya Derlemeleri]]></category>
		<category><![CDATA[Vitamin D]]></category>
		<guid isPermaLink="false"></guid>

					<description><![CDATA[Perinatal D vitamini yetersizliği Gül Yeşiltepe-Mutlu1, Şükrü Hatun2 Kocaeli Üniversitesi Tıp Fakültesi 1Pediatri Uzmanı, 2Pediatri Profesörü Çocuk Sağlığı ve Hastalıkları Dergisi 2011; 54: 87-98 Özet D vitamini yetersizliğine bağlı klinik problemler (rikets ve...]]></description>
										<content:encoded><![CDATA[<p><strong><span style="color:#5C3566;">Perinatal D vitamini yetersizliği </span></strong><br />
Gül Yeşiltepe-Mutlu1, Şükrü Hatun2<br />
Kocaeli Üniversitesi Tıp Fakültesi 1Pediatri Uzmanı, 2Pediatri Profesörü  </p>
<p><a href="http://www.cshd.org.tr/csh/pdf/pdf_CSH_421.pdf" target="_blank" rel="noopener">Çocuk Sağlığı ve Hastalıkları Dergisi 2011; 54: 87-98</a></p>
<p>Özet<br />
D vitamini yetersizliğine bağlı klinik problemler (rikets ve osteomalazi) halk sağlığındaki gelişmelere rağmen günümüzde de önemini korumaktadır. Son 20 yılda dikkatler anne ve bebeğin biyolojik birliği temelinde D vitamini eksikliğinin anne ve bebeğin ortak bir sorunu olduğuna yoğunlaşmış ve bu çerçevede perinatal D vitamini eksikliği tanımlaması önem kazanmıştır. Maternal D vitamini eksikliğinin yenidoğan ve bebeklik dönemindeki D vitamini eksikliği ve ‘infantil rikets’ için en önemli risk faktörü olmasının yanı sıra D vitamininin özellikle kemik dışı etkileri bakımından gebelik döneminin kritik bir dönem olabileceği, gebelikteki D vitamin eksikliğinin fetus üzerindeki etkilerinin yaşam boyu sürebileceği üzerinde durulmaktadır. Yenidoğan döneminden itibaren bütün bebeklere günde 400 IU D vitamini suplemantasyonu yapılması genel kabul görürken, gebelere yeterli dozda (2000 IU/gün) D vitamini suplemantasyonu yapılmadığı görülmektedir. Ülkemizde bütün bebeklere ücretsiz D vitamini verilmesine dayalı programın çok etkili olduğu görülmekle beraber maternal/perinatal D vitamini yetersizliğini önlemek amacıyla bu programın gebeleri kapsayacak şekilde genişletilmesine ihtiyaç vardır.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Blood biomarkers of vitamin D status</title>
		<link>https://wp.mikrobik.net/blood-biomarkers-of-vitamin-d-status/</link>
		
		<dc:creator><![CDATA[mikrobik]]></dc:creator>
		<pubDate>Wed, 10 Nov 2010 01:30:00 +0000</pubDate>
				<category><![CDATA[Biyokimya Derlemeleri]]></category>
		<category><![CDATA[biomarker]]></category>
		<category><![CDATA[Vitamin D]]></category>
		<guid isPermaLink="false"></guid>

					<description><![CDATA[Blood biomarkers of vitamin D status. Zerwekh JE Am J Clin Nutr. 2008 Apr;87(4):1087S-91S. In the past quarter century, more than 50 metabolites of vitamin D have been described. To date, only a...]]></description>
										<content:encoded><![CDATA[<p><strong><span style="color:#5C3566;">Blood biomarkers of vitamin D status.</span></strong><br />
Zerwekh JE</p>
<p><a href="http://www.ajcn.org/cgi/reprint/87/4/1087S" target="_blank" rel="noopener">Am J Clin Nutr. 2008 Apr;87(4):1087S-91S.</a></p>
<p>In the past quarter century, more than 50 metabolites of vitamin D have been described. To date, only a few of these have been quantified in blood, but this has widened our understanding of the pathologic role that altered vitamin D metabolism plays in the development of diseases of calcium homeostasis. Currently, awareness is growing of the prevalence of vitamin D insufficiency in the general population in association with an increased risk of several diseases. However, for many researchers, it is not clear which vitamin D metabolites should be quantified and what the information gained from such an analysis tells us. Only 2 metabolites, namely, 25-hydroxyvitamin D [25(OH)D] and 1,25-dihydroxyvitamin D [1,25(OH)2D], have received the greatest attention. Of these, the need for measuring serum 1,25(OH)2D is limited, and this metabolite should therefore not be considered as part of the standard vitamin D testing regimen. On the other hand, serum 25(OH)D provides the single best assessment of vitamin D status and thus should be the only vitamin D assay typically performed. Currently, numerous formats exist for measuring serum 25(OH)D concentrations, each with its own advantages and disadvantages. This article reviews the currently available methods for serum 25(OH)D quantitation and considers important issues such as whether both the D2 and the D3 forms of the vitamin should be assayed, whether total or free concentrations are most important, and what measures should be taken to ensure the fidelity of the measurements.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Vitamin D: An Evidence-Based Review</title>
		<link>https://wp.mikrobik.net/vitamin-d-an-evidence-based-review/</link>
		
		<dc:creator><![CDATA[mikrobik]]></dc:creator>
		<pubDate>Fri, 25 Dec 2009 10:40:00 +0000</pubDate>
				<category><![CDATA[Biyokimya Derlemeleri]]></category>
		<category><![CDATA[Vitamin D]]></category>
		<guid isPermaLink="false"></guid>

					<description><![CDATA[Vitamin D: An Evidence-Based Review Teresa Kulie, Amy Groff, Jackie Redmer, Jennie Hounshell and Sarina Schrager The Journal of the American Board of Family Medicine 22 (6): 698-706 (2009) Vitamin D is a...]]></description>
										<content:encoded><![CDATA[<p><strong><span style="color:#5C3566;">Vitamin D: An Evidence-Based Review</span></strong><br />
Teresa Kulie, Amy Groff, Jackie Redmer, Jennie Hounshell  and Sarina Schrager</p>
<p><a href="http://www.jabfm.org/cgi/reprint/22/6/698" target="_blank" rel="noopener">The Journal of the American Board of Family Medicine 22 (6): 698-706 (2009)</a> </p>
<p>Vitamin D is a fat-soluble vitamin that plays an important role in bone metabolism and seems to have some anti-inflammatory and immune-modulating properties. In addition, recent epidemiologic studies have observed relationships between low vitamin D levels and multiple disease states. Low vitamin D levels are associated with increased overall and cardiovascular mortality, cancer incidence and mortality, and autoimmune diseases such as multiple sclerosis. Although it is well known that the combination of vitamin D and calcium is necessary to maintain bone density as people age, vitamin D may also be an independent risk factor for falls among the elderly. New recommendations from the American Academy of Pediatrics address the need for supplementation in breastfed newborns and many questions are raised regarding the role of maternal supplementation during lactation. Unfortunately, little evidence guides clinicians on when to screen for vitamin D deficiency or effective treatment options.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>D Vitamini&#8217;nin Biyokimyasal ve Laboratuvar Değerlendirmesi</title>
		<link>https://wp.mikrobik.net/d-vitamininin-biyokimyasal-ve-laboratuvar-degerlendirmesi/</link>
		
		<dc:creator><![CDATA[mikrobik]]></dc:creator>
		<pubDate>Mon, 05 Jan 2009 09:15:00 +0000</pubDate>
				<category><![CDATA[Biyokimya Derlemeleri]]></category>
		<category><![CDATA[Vitamin D]]></category>
		<guid isPermaLink="false"></guid>

					<description><![CDATA[D Vitamini&#8217;nin Biyokimyasal ve Laboratuvar Değerlendirmesi Belkız Öngen, Ceyda Kabaroğlu, Zuhal Parıldar Türk Klinik Biyokimya Derg 2008; 6(1): 23-31 &#8220;D vitamininin en önemli etkisi, kalsiyu m homeostazı ve kemik sağlığı üzerinedir. Ayrıca D...]]></description>
										<content:encoded><![CDATA[<p><strong><span style="color:#5C3566;">D Vitamini&#8217;nin Biyokimyasal ve Laboratuvar Değerlendirmesi</span></strong><br />
Belkız Öngen, Ceyda Kabaroğlu, Zuhal Parıldar</p>
<p><a href="http://tkb.dergisi.org/pdf/pdf_TKB_99.pdf" target="_blank" rel="noopener">Türk Klinik Biyokimya Derg 2008; 6(1): 23-31</a></p>
<p>&#8220;D vitamininin en önemli etkisi, kalsiyu m homeostazı ve kemik sağlığı üzerinedir. Ayrıca D vitamini hormon gibi fonksiyon görerek kolon kanseri, prostat kanseri, akciğer kanseri gibi kanserleri, Multipl Skleroz, Tip 1 Diyabet, Crohn Hastalığı, Metabolik Sendrom gibi otoimmun hastalıkları ve tüberküloz gibi enfeksiyon hastalıklarını önlemede anahtar rolü oynamaktadır. D Vitamini eksikliği 25(OH)D düzeyinin 20 ng/ml&#8217;den az olması olarak tanımlanmaktadır. Çocuklarda raşitizm, yetişkinlerde osteomalaziye yol açan kemik demineralizasyonuna neden olmaktadır. Bu derlemede D vitamininin metabolizması, fonksiyonu, düzeyleri, ölçüm yöntemleri, eksikliğinin nedenleri, klinik ve biyokimyasal değerlendirmesi, otoimmun, kardiyovaskuler hastalıklar, osteoporoz ve kanser ile olan ilişkisi değerlendirilmiştir.&#8221;</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
